Clinical Trials Logo

Advanced Prostate Cancer clinical trials

View clinical trials related to Advanced Prostate Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06095089 Recruiting - Clinical trials for Advanced Prostate Cancer

A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer

Start date: November 1, 2023
Phase: Phase 1
Study type: Interventional

The purpose of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 (Part 1: dose escalation) and further evaluate the safety at RP2Rs (Part 2: dose expansion) in participants with advanced prostate cancer.

NCT ID: NCT05942001 Recruiting - Clinical trials for Advanced Prostate Cancer

Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Start date: September 15, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerability and preliminary efficacy of HRS-5041 in men with progressive metastatic castration resistant prostate cancer. The objective of this study was to determine the dose-limiting toxicity, maximum tolerance and recommended dose of HRS-5041 in phase II study.

NCT ID: NCT05800665 Recruiting - Clinical trials for Metastatic Prostate Cancer

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

Start date: May 2, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or metastatic prostate cancer. It will also identify recommended doses and regimens for RO7656594 for subsequent studies.

NCT ID: NCT03938649 Recruiting - Clinical trials for Advanced Prostate Cancer

SRAM study_Postate Cancer

Start date: May 15, 2019
Phase: Phase 2
Study type: Interventional

This is a phase 2 randomized study for High risk localized prostate cancer (T3 to T4 disease and/or PSA > 20 and/or Gleason score ≥ 8) without evidence of distant and nodal metastasis. Patient will be randomized to:Arm 1 - Conventional IMRT RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes). - 38 fractions of daily treatment, Monday to Friday or Arm 2 SBRT - RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes) - 5 fractions of weekly treatment. Once fraction per week. All patients will be given neoadjuvant and adjuvant androgen deprivation therapy (detail as below)

NCT ID: NCT03936218 Recruiting - Clinical trials for Advanced Prostate Cancer

Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer

Start date: September 30, 2020
Phase: Phase 3
Study type: Interventional

A two arm, multi centric, randomized, open label, parallel, two doses pharmacodynamics study in patients with advanced prostate cancer.